Abstract

An embodiment in accordance with the present invention provides a catheter solution that would maintain MRI-compatible metallic braiding or metallic covering on a surface of the catheter, and that also prevents cables disposed in an interior lumen of the catheter from effectively propagating currents induced from external signal transmissions, which could cause a rise in temperature of the cables themselves and of tissues surrounding the catheter. The present invention uses metals which are non-ferromagnetic and not highly paramagnetic, so they do not cause large susceptibility artifacts in the MRI field. The construction of the braid prevents most of the RF fields from penetrating into the anterior of the catheter. Therefore, there is no need or a reduced need to add heat amelioration components to each electrical cable inside the catheter.

IPC Classes  ?

• G01R 33/28 - Details of apparatus provided for in groups
• A61M 25/00 - CathetersHollow probes
• G01R 33/36 - Electrical details, e.g. matching or coupling of the coil to the receiver

Abstract

CeO2 nanoparticles having a copper domain disposed on at least a portion of the nanoparticle. The material can catalyze a nitrogen oxide decomposition, such as a deNxOy reaction. Methods of making and using the material are also provided.

IPC Classes  ?

• B01J 23/83 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups with rare earths or actinides
• B01D 53/86 - Catalytic processes
• B01J 6/00 - CalciningFusing
• B01J 35/40 - Catalysts, in general, characterised by their form or physical properties characterised by dimensions, e.g. grain size
• B01J 35/50 - Catalysts, in general, characterised by their form or physical properties characterised by their shape or configuration
• B01J 37/03 - PrecipitationCo-precipitation
• B01J 37/04 - Mixing

Abstract

A formulation of netarsudil has been developed which is efficacious with reduced redness and pain. The formulation appears to deliver at least as much drug to the eye in animal studies based on the demonstration that it reduced IOP at least as well as did RHOPRESSA®. The data shows improved IOP lowering efficacy with higher concentrations of netarsudil, while still reducing key side effects like ocular redness, as compared to RHOPRESSA®.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers

Abstract

Removing metal from metal-carbon material includes contacting the metal-carbon material with hydrogen chloride, thereby yielding a metal chloride in the gas phase and a solid product comprising carbon. The metal-carbon material and the solid product may both contain elemental carbon. A concentration of metal in the solid product is typically less than 1 wt %.

IPC Classes  ?

• C01B 32/162 - Preparation characterised by catalysts
• C01B 32/05 - Preparation or purification of carbon not covered by groups , , ,
• C01G 53/09 - ChloridesOxychlorides

Abstract

This document relates to methods and materials for treating a mammal (e.g., a human) having, or at risk of having, a heart attack (also called a myocardial infarction). For example, one or more inhibitors of a period circadian protein (PER) polypeptide can be administered to a mammal (e.g., a human) having, or at risk of having, a heart attack to treat the mammal.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/04 - Nitro compounds
• A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Methods for treating age-related sarcopenia and/or enhancing longevity by administering one or more GCPII inhibitors, wherein the one or more GCPII inhibitors are selected from a phosphonate-based GCPII inhibitor, a phosphinate-based GCPII inhibitor, a phosphoramidate-based GCPII inhibitor, a thiol-based inhibitor, a hydroxamate-based inhibitor, and a urea-glutamate based GCPII inhibitor, including one or more of 2-PMPA and prodrugs thereof, L-DOPA, D-DOPA, caffeic acid, and prodrugs thereof, a hydroxamate-based prodrug, and a dendrimer 2-PMPA conjugate are disclosed.

IPC Classes  ?

• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

Provided herein are methods and materials for detecting and/or treating subject (e.g., a human) having cancer. In some embodiments, methods and materials for identifying a subject as having cancer (e.g., a localized cancer) are provided in which the presence of member(s) of two or more classes of biomarkers are detected. In some embodiments, methods and materials for identifying a subject as having cancer (e.g., a localized cancer) are provided in which the presence of member(s) of at least one class of biomarkers and the presence of aneuploidy are detected. In some embodiments, methods described herein provide increased sensitivity and/or specificity in the detection of cancer in a subject (e.g. a human).

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/6858 - Allele-specific amplification
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6869 - Methods for sequencing

Abstract

Methods of predicting risk of subsequent diseases following Toxoplasma infection in multiple at-risk populations including patients with ocular toxoplasmosis or congenital toxoplasmosis, transplant recipients and other immunosuppressed patients with prior exposure to toxoplasma. The methods include the use of synthetic modified Toxoplasma cyst peptides.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C07K 14/45 - Toxoplasma

Abstract

The present disclosure provides methods of treating and preventing trigeminal nerve pain with modulators of oxidative stress (e.g., NRF2 transcription network activators and/or inhibitors of transient receptor potential ankyrin 1 (TRPA1)) and compositions thereof.

IPC Classes  ?

• A61K 33/24 - Heavy metalsCompounds thereof
• A61K 31/26 - Cyanate or isocyanate estersThiocyanate or isothiocyanate esters
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/5685 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone having an oxo group in position 17, e.g. androsterone
• A61P 25/04 - Centrally acting analgesics, e.g. opioids

Abstract

The present disclosure relates to methods of screening compounds which reduce or inhibit SUN1 in neuronal cells or a population of cells and methods of inhibiting SUN1 expression in a cell to treat one or more subjects suffering from one or more neurodegenerative diseases.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

A series of albumin-binding radiolabeled PSMA-based low-molecular-weight radiotherapeutics comprising a DOTA chelator used as a complexing agent for a radiometal, such as 177Lu, albumin-binding moieties, such as 4-(p-iodophenyl)butyric acid moiety (I PBA) and ibuprofen (IBU), fatty acids, an amino acid urea moiety, and a linker, and their use for treating one or more PSMA expressing tumors or cells, including prostate cancer, are disclosed.

IPC Classes  ?

• C07D 257/02 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
• A61K 51/04 - Organic compounds
• A61P 13/08 - Drugs for disorders of the urinary system of the prostate
• A61P 35/00 - Antineoplastic agents
• C07B 59/00 - Introduction of isotopes of elements into organic compounds

Abstract

A system for drilling and injection includes an imaging system, a robotic arm, and an end effector coupled to an end of the robotic arm and operable as a drill component and as an injector component. The end effector includes a housing that is configurable to attach the end effector to the robotic arm, a linear guide having a distal end and a lumen having a dimension sufficient to allow a drill bit and a cannula to pass therethrough, and a switch block mounted to the housing. The switch block receives the drill bit as the drill bit passes through said linear guide and extends beyond the distal end. The switch block includes a stop to prevent the drill bit from extending a length beyond the distal end. The switch receives the cannula as the cannula passes through the linear guide and extends beyond the distal end.

IPC Classes  ?

• A61B 34/37 - Leader-follower robots
• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
• G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices

Abstract

Compositions and methods are provided for treating ischemic conditions such as myocardial infarction, myocardial ischemia, or ischemia reperfusion injury in a subject in need thereof. In particular, the methods comprise administering a therapeutically effective amount of programmed death ligand-1 (PD-L1) to a subject.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

The present disclosure relates to compounds that can be used in the treatment of cancer, such as prostate cancer. The disclosure also relates to pharmaceutical compositions comprising the prodrugs, and related methods of treatment.

IPC Classes  ?

• C07D 215/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61P 35/00 - Antineoplastic agents

Abstract

Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off-target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.

IPC Classes  ?

• A61K 51/04 - Organic compounds
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61P 35/00 - Antineoplastic agents
• C07B 39/00 - Halogenation
• C07B 59/00 - Introduction of isotopes of elements into organic compounds

Abstract

A system includes a first device configured to be in contact with a patient. The system also includes a stimulator configured to be in contact with the patient. The stimulator is configured to transmit one or more first bits to the patient. The system also includes a receiver configured to be in contact with the patient. The one or more first bits are configured to travel from the stimulator, through a nerve in a limb of the patient, to the receiver. The receiver is configured to cause the first device to wirelessly transmit one or more second bits to the stimulator in response to the receiver receiving the one or more first bits.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

Techniques for assessing a visual field of a patient are presented. The techniques use a system that includes: an immersive headset; a patient input device; and an electronic processor coupled to the immersive headset and to the patient input device, where the electronic processor is configured to perform actions that include: causing the immersive headset to display a first sequence of stimuli to a first eye of the patient, where respective locations of individual stimuli from the first sequence of stimuli are selected from among locations that are equidistantly spaced within quadrants of a field of view of the first eye of the patient; receiving, from the patient input device, responses indicative of whether the patient perceived individual of the first sequence of stimuli; adapting the first sequence of stimuli based at least on the responses; and reporting a patient visual deficit pattern based on the causing and the receiving.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G06N 20/00 - Machine learning

Abstract

Disclosed are methods for identifying a severity and/or survival risk in a subject having or at risk of developing PAH, the method comprising the step of measuring ST2, IGFBP1, IGFBP2, IGFBP4, Endostatin, and Galectin-3 in a sample obtained from the subject, to identify the severity and/or survival risk associated with PAH in the subject. The methods also include treating the subject once the severity and/or survival risk of PAH is identified.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones
• G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard

Abstract

Disclosed are methods for adding a sequence to an oligonucleotide to create a custom targeting oligonucleotide. The custom targeting oligonucleotides can be used in methods to enhance single cell sequencing platforms to allow highly targeted capture of nucleotide sequences.

IPC Classes  ?

• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C40B 20/04 - Identifying library members by means of a tag, label, or other readable or detectable entity associated with the library members, e.g. decoding processes
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• C12Q 1/6855 - Ligating adaptors
• C12Q 1/6869 - Methods for sequencing

Abstract

According to various embodiments, machine learning techniques for determining a pharmacokinetic parameter of a radiotracer in a patient are presented. The techniques include: obtaining a time sequence of positron emission tomography (PET) scans of a target tissue of the patient, where the time sequence of PET scans includes images of a radiotracer in the target tissue; providing the time series of the PET scans to a first neural network system, which provides features extracted from the time series of the PET scans; providing the features extracted from the time series of the PET scans to a second neural network system, which provides an estimated arterial input function; modeling the pharmacokinetic parameter of the radiotracer based on the estimated arterial input function and the time sequence of PET scans; and outputting an estimate of the pharmacokinetic parameter of the radiotracer based on the modeling.

IPC Classes  ?

• G06N 3/0895 - Weakly supervised learning, e.g. semi-supervised or self-supervised learning
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Compositions and methods are provided for analyzing repeat sequences in genomes are utilized in methods for large-scale analyses of these regions for characterization, detection and monitoring of human cancer.

IPC Classes  ?

• G16B 30/10 - Sequence alignmentHomology search
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

A self-monitoring cerebrospinal fluid (CSF) shunt includes a CSF shunt defining a fluid path from a proximal end to a distal end thereof; and a monitoring device arranged proximate at least a portion of the CSF shunt. The monitoring device includes at least one of an optical transmitter or an ultrasound transmitter arranged to transmit corresponding optical or acoustic waves into said fluid path defined by the CSF shunt, a detector arranged to detect the at least one of optical or acoustic waves after being at least one of scattered or absorbed from a plurality of particles when present in the fluid path defined by the CSF shunt, and an electronic module that includes a data processor configured to communicate with the detector. The data processor is further configured determine at least one of a presence of the plurality of particles, a size of the plurality of particles, a density of the plurality of particles, a type of the plurality of particles, or a motion of the plurality of particles when present in the fluid path of the CSF shunt.

IPC Classes  ?

• A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Disclosed are methods for imaging inflammation associated with inflammatory bowel disease (IBD), including administering to a subject a prostate-specific membrane antigen (PSMA)-targeted imaging agent and taking an image.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 49/00 - Preparations for testing in vivo
• A61B 6/03 - Computed tomography [CT]
• A61K 51/04 - Organic compounds
• A61N 5/06 - Radiation therapy using light

Abstract

A catheter deployment device including a housing; and a panel coupled to the housing. The panel extends from the housing at an angle and the panel includes an aperture. The deployment device further includes a deployment assembly coupled to the housing. The deployment assembly is aligned with the aperture along an insertion axis.

IPC Classes  ?

• A61M 25/09 - Guide wires
• A61M 25/06 - Body-piercing guide needles or the like
• A61M 29/00 - Dilators with or without means for introducing media, e.g. remedies

Abstract

Provided is a functional, low-profile intercranial device (LID). The LID includes a base portion; at least one cavity associated with the base portion and configured to accept at least one functional component; and at least one conduit having a first end in communication with the at least one cavity. The at least one functional component includes a medicinal, electronic, or optic therapeutic. The at least one conduit is configured to accept the medicinal therapeutic and a second end configured to dispense the therapeutic.

IPC Classes  ?

• A61F 2/28 - Bones
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/03 - Measuring fluid pressure within the body other than blood pressure, e.g. cerebral pressure
• A61B 5/369 - Electroencephalography [EEG]
• A61F 2/30 - Joints
• A61F 2/48 - Operating or control means, e.g. from outside the body, control of sphincters
• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61N 1/00 - ElectrotherapyCircuits therefor
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for detecting and treating prostate cancer. In a specific embodiment, a method for identifying a patient as having aggressive prostate cancer comprising the step of detecting overexpression relative to a control of epithelial cell adhesion molecule (EpCAM), H4 clustered histone 5 (H4C5), and tetratricopeptide repeat domain 3 (TTC3) in a urine sample obtained from the patient. In a more specific embodiment, the detecting step comprises detecting protein or ribonucleic acid (RNA) level of EPCAM, H4C5 and TTC3. In another specific embodiment, the method further comprises detecting overexpression relative to a control of one or more of messenger ribonucleic acid (mRNA), circulating RNA (circRNA), extracellular DNA and long non-coding RNA (lncRNA). The method can further comprise detecting metabolites.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Conjugation of dendrimer molecules with one or more carbohydrate moieties significantly enhances targeting of tumor-associated macrophages (TAMs) and microglia by increasing brain penetration and cellular internalization, as compared with dendrimers without modification with carbohydrate molecules. Compositions of dendrimers conjugated with carbohydrate moieties, particularly glucose and/or glucosamine, and one or more active agents to prevent, treat, or diagnose a disease or disorder in a subject in need thereof, and methods of use thereof, have been developed. The compositions are particularly suited for treating and/or ameliorating brain and/or CNS tumors. Methods of treating a human subject having or at risk of brain and/or CNS tumors are provided.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes

Abstract

A battery housing may include a primary vent channel, auxiliary vent channels, and receptacles for receiving cells. Each receptacle may have sidewalls that operate as barriers to cell venting events occurring in other receptacles, an auxiliary vent channel opening to a respective auxiliary vent channel, and a primary vent channel opening to the primary vent channel. Each primary vent channel opening may be aligned with a position of a vent valve of a cell disposed within a respective receptacle such that internal substances expelled from the vent valve or a rupture at the vent valve in an associated vent direction are directed into the primary vent channel. Each auxiliary vent channel opening is not aligned with a respective primary vent channel opening and a respective position of a vent valve.

IPC Classes  ?

• H01M 50/367 - Internal gas exhaust passages forming part of the battery cover or caseDouble cover vent systems
• H01M 50/229 - Composite material consisting of a mixture of organic and inorganic materials
• H01M 50/244 - Secondary casingsRacksSuspension devicesCarrying devicesHolders characterised by their mounting method
• H01M 50/293 - MountingsSecondary casings or framesRacks, modules or packsSuspension devicesShock absorbersTransport or carrying devicesHolders characterised by spacing elements or positioning means within frames, racks or packs characterised by the material
• H01M 50/342 - Non-re-sealable arrangements

Abstract

A microcapsule includes an oxime-based polymerization product of two or more monomers and a payload. The payload may be encapsulated within the microcapsule. The oxime-based polymerization products may include an oxime-based monomer and an isocyanate-based monomer. Methods of making such microcapsules and methods of delivering a payload to a target using such microcapsules are provided.

IPC Classes  ?

• A61K 9/50 - Microcapsules
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention provides a method and device for non-invasive anatomical and systemic cooling, fluid removal and/or energy removal. The method and device provide for removal of fluid and cooling of various bodily fluid-containing spaces or surfaces, such as mucus-containing spaces or surfaces via delivery of a dry fluid not including a coolant into or upon the mucus-containing space or surface. Exposure of such mucus to the dry fluid results in evaporation of body fluid, removal of energy, cooling of the anatomical feature, and systemic cooling. In this fashion, therapeutic hypothermia may be achieved to provide for neuroprotection of various organs after ischemic insult, such the brain after cardiac arrest. Similarly, excess fluid removal may be achieved for treatment of cardiogenic shock or other conditions that cause significant fluid build-up, especially in cases of compromised renal function. Additionally, the invention may be used to reduce fever, and other conditions where removal of heat, energy and/or water are beneficial.

IPC Classes  ?

• A61F 7/00 - Heating or cooling appliances for medical or therapeutic treatment of the human body
• A61F 7/12 - Devices for heating or cooling internal body cavities

Abstract

Compounds and methods for treating proteotoxicity-associate diseases, including neurodegenerative diseases, such as Alzheimer's disease (AD), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS), are disclosed.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine

Abstract

Compounds and method for treating a disease, condition, or disorder associated with serotonin (5-HT) signaling, including gastroenterological disorders, such as colitis, irritable bowel syndrome (IBS), constipation, diarrhea, and gastroparesis, or extra-gastrointestinal disorders, such as asthma, migraine, itching, and osteoporosis. In some aspects, the compounds inhibit serotonin/5-HIT transporter (SERT).

IPC Classes  ?

• C07D 211/34 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
• A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

A device for magnetic resonance artifact correction includes an array of shim coils sequentially arranged to receive a current, such that a first force arising from an interaction of a magnetic field with the current in one shim coil is balanced by a second force on the array arising from interactions of the magnetic field with the current in other shim coils when the array is operated within an imaging volume of a magnetic resonance system. The device includes a frame of non-ferromagnetic material, to provide selectable positioning of the array, and a signal processor to use a measurement of a magnetic field inhomogeneity within a region of the imaging volume, to determine a current for the shim coils and coordinates for positioning the array within the imaging volume, such that applying the current to the array at the coordinates generates a correction field to reduce the magnetic field inhomogeneity.

IPC Classes  ?

• G01R 33/3875 - Compensation of inhomogeneities using correction coil assemblies, e.g. active shimming
• G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities

Abstract

Provided herein are methods of reconstructing computed tomography (CT) images and methods of generating artificial neural networks (ANNs) to estimate unmodeled bias from acquired CT projection data. Related systems and computer program products are also provided.

IPC Classes  ?

• G06T 11/00 - 2D [Two Dimensional] image generation

Abstract

Provided herein are methods of detecting pancreatic cancer in a subject, the method comprising measuring in a sample from the subject a level of CA19-9 polysaccharide relative to a reference, and a level of a polynucleotide or polypeptide of at least one marker selected from the group consisting of: OPN, MIA, CEACAM-1, MIC-I, SPONI, HSP27, POSTN, and LGALS3BP relative to a reference, wherein an increased level of the CA19-9 polysaccharide relative to a reference and an increased level of the polynucleotide or polypeptide relative to a reference indicates presence of pancreatic cancer in the subject.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

A submersible vehicle may include a propulsion assembly, a pressure vessel, and a floodable actuator vessel. A bulkhead may seal a pressure shell of the pressure vessel to prevent fluid intrusion into an interior cargo compartment of the pressure shell when the submersible vehicle is submersed into a fluid. The floodable actuator vessel may be coupled to the pressure vessel and may include a floodable shell and a plurality of actuators. The floodable shell may include a plurality of flood openings configured to permit fluid intrusion into an interior flood space of the floodable shell when the submersible vehicle is submersed into a fluid. Each actuator may be disposed within the interior flood space and affixed to an interior surface of the floodable shell at an actuator opening through which an external fin is actuated to maneuver the submersible vehicle in coordination with the propulsion assembly.

IPC Classes  ?

• B63G 8/22 - Adjustment of buoyancy by water ballastingEmptying equipment for ballast tanks
• B63G 8/04 - Superstructure
• B63G 8/08 - Propulsion

Abstract

Described are nucleic acid transcription templates, systems and methods for detection and measurement of molecules (e.g., proteins or polypeptides, small molecules, metabolites, cofactors, ions). Particularly, systems and methods utilize a transcription template with an aptamer domain configured to bind a molecule of interest to regulate production of a transcribed output RNA.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

Provided herein are nucleic acid vaccine constructs comprising synthetic polynucleotides encoding a severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) protein, or a functional portion, fragment, or variant thereof, conjugated to a macrophage inflammatory protein-3 alpha (MIP-3a) or other chemokine that binds to a chemokine receptor 6 (CCR6), or a functional portion, fragment, or variant thereof, or to an antibody, or antigen binding portion thereof, that binds to a CCR6. Methods for making the vaccine constructs and their use in prophylaxis and treatment of SARS-CoV-2 infections are also provided.

IPC Classes  ?

• A61K 39/125 - Picornaviridae, e.g. calicivirus
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/52 - CytokinesLymphokinesInterferons
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

Pre-infection HIV antibody reactivities were identified that correlated with post-infection VL. Pre-infection reactivity to an epitope in the 1IR2 domain of gp4I was associated with controller status and lov/er VL. Pre-infection reactivity to an epitope in the C2 domain of gpl20 was associated with non-controller status and higher VL. Different patterns of antibody reactivity were observed over time for these two epitopes.

IPC Classes  ?

• C07K 14/16 - HIV-1
• C07K 14/08 - RNA viruses
• C07K 14/155 - Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus

Abstract

Provided herein are methods of producing a trained model for generating peptide or protein sequence information and infilling of targeted residue spans. In some embodiments, the methods include training a model using a training dataset comprising a population of reference amino acid sequence representations in which a given amino acid sequence representation in the population is conditioned on one or more conditioning tags that provide a controllable generation of selected amino acid sequence representation types. Related methods, systems, and computer program products are also provided.

IPC Classes  ?

• G16B 35/10 - Design of libraries
• G16B 40/20 - Supervised data analysis

Abstract

A series of peptide-drug conjugates that react with multi-arm polyethylene glycol (PEG) to form chemically cross-linked hydrogels and their use as both a sealant and a therapeutic depot is disclosed.

IPC Classes  ?

• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 47/02 - Inorganic compounds
• A61P 35/00 - Antineoplastic agents

Abstract

Pharmaceutical compositions which either induce transient epithelial-mesenchymal transition (EMT) in epithelial cells, or inhibit fibroblast and immune cell migration, in the treatment of diseases or conditions associated with build-up of viscous extracellular fluids. Delivery vehicles include the use of mucus-penetrating nanoparticles

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 471/04 - Ortho-condensed systems
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

Described herein are methods and compositions for assessing a mammal having or suspected of having cancer and/or for treating a mammal having cancer. For example, molecules including one or more antigen-binding domains (e.g., a single-chain variable fragment (scFv)) that can bind to a modified peptide (e.g., a tumor antigen), as well as method for using such molecules, are provided.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

Computer-implemented neural network techniques for predicting patient-specific arrhythmic sudden cardiac death survival are presented. The techniques can include obtaining cardiac image data for a patient; obtaining cardiac covariate data for the patient; providing the cardiac image data to a first subnetwork; providing the cardiac covariate data to a second subnetwork; combining an output from the first subnetwork with an output from the second subnetwork to produce survival probability data; and outputting patient-specific arrhythmic sudden cardiac death survival prediction data based on the survival probability data.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present disclosure relates to compositions and methods for modulating wound healing and regeneration. More particularly, the present disclosure relates to immunomodulatory agents that promote wound healing and tissue regeneration, and that may be optionally used in combination with synthetic or bio-material scaffolds.

IPC Classes  ?

• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/24 - Collagen
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof

Abstract

Systems and methods for segmenting an image provided by OCTA using a trained model are provided. Methods include processing a plurality of paired training image sets using a first neural network to separate, from each of the paired training image sets, a respective anatomy component from a respective contrast component of a respective image subject, and processing second training images using a second neural network to generate, from the second training images, a representation of a respective delineated image. The first neural network can include a conditioning network for receiving one of the paired training images, and an encoder a decoder for receiving and processing the other of the paired training images. The second neural network can include the conditioning network, configured to receive the second training images, and a segmenter configured to produce a representation of the delineated image.

IPC Classes  ?

• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06N 3/02 - Neural networks

Abstract

As cell-free DNA from brain and spinal cord tumors cannot usually be detected in the blood, we assessed the cerebrospinal fluid (CSF) that bathes the CNS for tumor DNA, here termed CSF-tDNA. The results suggest that CSF-tDNA could be useful for the management of patients with primary tumors of the brain or spinal cord.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

A method for obtaining a contrast distribution includes acquiring pre-contrast spectral data before contrast is administered, acquiring post-contrast spectral data after the contrast is administered, and generating at least one material basis map for at least one material by joint processing the pre-contrast spectral data and the post-contrast spectral data to solve for a pre-selected number of unknowns corresponding to the at least one material associated with the at least one material basis map. The method also includes where the joint processing enables visualization of contrast distribution from contrast agent injection or drug delivery contrast agents, and where the at least one material basis map includes the contrast distribution.

IPC Classes  ?

• G16H 30/00 - ICT specially adapted for the handling or processing of medical images

Abstract

Provided herein are methods of calibrating fluorescent signals emitted by fluorescent protein (FP) biosensors that include detecting fluorescent signals emitted by one or more FP biosensors and one or more fluorescent calibration standard biomolecules in a cell population to produce a detected FP biosensor signal data set and a detected calibration standard signal data set, wherein the FP biosensors comprise at least a first set of one or more FPs, or functional portions thereof, and wherein the calibration standard biomolecules comprise at least a second set of one or more FPs, or functional portions thereof, and normalizing the detected FP biosensor signal data set to the detected calibration standard signal data set. Related methods, compositions, kits, systems, and computer readable media are also provided.

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence
• G06T 7/00 - Image analysis
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

A series of peptide-drug conjugates that react with multi-arm polyethylene glycol (PEG) to form chemically cross-linked hydrogels and their use as both a sealant and a therapeutic depot is disclosed.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 35/00 - Antineoplastic agents

Abstract

Fluoroquinolones and aminoglycoside ion-paired crystalline formulations have been developed which bypass the need for frequent dosing. The crystal formulations are made by anionic ion-pairing. These crystal formulations have a slower and more uniform rate of dissolution than the amorphous or other crystalline forms of fluoroquinolones and aminoglycosides so can be suspended in aqueous solution for sustained release. Examples demonstrate ion-paired crystals of moxifloxacin and besifloxacin.

IPC Classes  ?

• A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems

Abstract

inter aliainter alia, cell culture media for cell-transfection or intracellular delivery, and methods and kits using the same.

IPC Classes  ?

• C12N 5/07 - Animal cells or tissues

Abstract

A method for physiological detection and alerting is disclosed that includes obtaining biometric sensor data from a user; generating processed biometric sensor data from the set of biometric sensor data; generating features from the processed biometric sensor data which are associated with one or more characteristic physiological event phase; determining, the set of processed biometric sensor data, or both, a confidence score for each characteristic physiological event phase of the characteristic physiological event phases indicating a presence of that phase in a data segment; determining a final confidence score indicating an occurrence of a physiological event based on a relation between the confidence scores of all the characteristic physiological events; determining a cumulative confidence score indicating an occurrence of a particular physiological event, wherein the physiological event comprises of characteristic physiological event phases; and providing a potential physiological event alert based on the cumulative confidence score.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

Examples may provide a method of selecting data as part of an active learning process. The method includes extracting features from different classes of medical image datasets using a self-supervised contrastive learning technique to produce a set of extracted image features. The method also includes assigning clusters to achieve label diversity using the set of extracted image features to produce a set of clusters. In addition, the method also includes selecting hard-to-contrast data points from dataset maps, wherein a hard-to-contrast data point in a given cluster from the set of clusters is harder to contrast itself with other data points in the given cluster. Examples may also provide a method of segmenting an image using a contrastive language-image pre-training (CLIP)-driven universal model. Additional methods as well as related systems and computer readable media are also provided.

Abstract

Biodegradable cationic polyesters for intramuscular delivery of nucleic acids, including self-amplifying mRNA, and methods of their use for treating conditions or diseases are disclosed.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

Disclosed herein is a device for electrochemical experimentation comprising a reaction well holder, a gasket, and a top plate. The reaction well holder is comprised of a plurality of reaction wells, electrodes, and electrical contacts. The gasket and top plate are attached in such a fashion that each reaction well is sealed in an air-tight fashion. Once assembled this device can be mounted on a potentiostat of electrochemical experimentation can be carried out under an inert atmosphere and each reaction well may be sampled without the disassembly of the device.

IPC Classes  ?

• G01N 27/28 - Electrolytic cell components
• G01N 27/30 - Electrodes, e.g. test electrodesHalf-cells
• G01N 27/403 - Cells and electrode assemblies

Abstract

Provided herein are systems, kits, compositions and methods for sequencing library preparation and sequencing workflow (e.g., for the identification of mutations). In certain embodiments, provides herein systems and methods to identically barcode both strands of templates, and PCR-based enrichment of each strand that does not require hybridization capture.

IPC Classes  ?

• C12Q 1/6855 - Ligating adaptors
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

Compounds and their use in treating a condition, disease, or disorder associated with an increased neutral sphingomyelinase 2 (nSMase2) activity or expression are disclosed.

Abstract

A supramolecular filament comprising an ACE2-binding ligand peptide amphiphile, a self-assembling filler peptide amphiphile, and a soluble ACE; and related compositions, respirable aerosols or nasal sprays, and methods for treating or preventing a viral infection are disclosed.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 31/14 - Antivirals for RNA viruses

Abstract

A nasal trans-esophageal echocardiography system includes a nasal trans-esophageal device comprising a sheath defining a lumen therein, the sheath having a width sufficiently narrow to fit through a nasal passage of a subject, an ultrasound probe having a width sufficiently narrow to extend through said lumen defined by said sheath, and a workstation configured to communicate with said ultrasound probe to receive ultrasound signals from said ultrasound probe and to form ultrasound images based on said ultrasound signals.

IPC Classes  ?

• A61B 8/12 - Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• A61B 8/08 - Clinical applications

Abstract

An image-guided robotic spine injection system includes an injection robot registered to an interoperative imaging system for real-time guidance. The system includes a guidance system to communicate with said injection robot and said interoperative imaging system during an injection procedure. The guidance system includes a preoperative injection plan based on preoperative imaging data of a subject's spine, and includes anatomical features identified as preoperative registration markers. The guidance system receives interoperative imaging data from said interoperative imaging system of said subject's spine. The guidance system receives an indication of anatomical features identified as interoperative registration markers that correspond in a one-to-one relationship to each of said preoperative registration markers. The guidance system registers said interoperative registration markers with said preoperative registration markers to transform said preoperative injection plan to an interoperative injection plan. The guidance system provides instructions to said injection robot to perform autonomous injections into said subject's spine.

IPC Classes  ?

• A61B 34/32 - Surgical robots operating autonomously
• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
• A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

Provided herein are methods for increasing the therapeutic efficiency of oncolytic bacterial therapeutics. Bacterial oncolytic therapies, especially the ones targeting tumor hypoxia such as C. novyi-NT, often encounter incomplete tumor clearance in less hypoxic tumoral areas and severe inflammatory reactions. In this study, we explored immune-modulating preconditioning to suppress the host neutrophils and significantly enhanced the antitumor efficacy of C. novyi-NT in animal models, including an orthotopic brain tumor model in rabbits. The optimized preconditioning agent, hydroxyurea, is clinically approved and C. novyi-NT has demonstrated manageable safety and promising antitumor responses in clinical trials. Thus, the proposed preconditioning of neutrophil suppression is readily translatable to patients undergoing C. novyi-NT trials or other oncolytic biologic therapies and could improve outcome.

IPC Classes  ?

• A61K 31/133 - Amines, e.g. amantadine having hydroxy groups, e.g. sphingosine
• A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The invention provides compositions and methods for the preparation of processed adipose tissue. The invention further provides methods of use of the processed adipose tissue.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 35/35 - Fat tissueAdipocytesStromal cellsConnective tissues
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof

Abstract

An extracellular matrix (ECM) mixture and ECM scaffolds made with same are disclosed. The ECM mixture can comprise from about 5% to about 85% by weight of ECM material and from about 15% to about 95% by weight of a polymer material, such as, but not limited to, a biodegradable polyester. The presently disclosed anatomically-shaped porous ECM scaffolds can be formed, for example, using a three-dimensional (3D) printing process, an injection molding process, or any other process.

IPC Classes  ?

• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/16 - Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/56 - Porous or cellular materials
• B33Y 10/00 - Processes of additive manufacturing
• C08L 29/04 - Polyvinyl alcoholPartially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids

Abstract

Methods for preparing one or more nanoparticles comprising an amphiphilic block copolymer having a polyelectrolyte complex comprising one or more therapeutic small proteins and a counter ion polymer encapsulated therein and their use for treating peripheral nerve injuries are disclosed.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 9/50 - Microcapsules
• A61K 38/30 - Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

A customized external cranioplasty includes a rigid section and a rim at least one of attached to or integral with the rigid section and extending at least partially around a periphery of the rigid section. The rigid section has a size and shape to substantially match a cranial defect and includes an impact-resistant material to provide protection and support to a user due to the cranial defect. The rim facilitates secure and comfortable contact of the customized external cranioplasty to the user's head. A method of producing a customized external cranioplasty includes receiving three-dimensional imaging data for at least a portion of a subject's skull that has a cranial defect: segmenting the cranial defect region from a surrounding portion of the subject's skull to obtain a surface requiring support by the customized external cranioplasty; and producing a rigid section of the customized external cranioplasty using said surface requiring support obtained from the segmenting.

IPC Classes  ?

• A61F 13/12 - Bandages or dressingsAbsorbent pads specially adapted for the head or neck
• A61F 13/00 - Bandages or dressingsAbsorbent pads
• A61F 13/01 - Non-adhesive bandages or dressings

Abstract

The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immunosuppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-β)) and regulatory T cells and/or immunosuppressive myeloid dendritic cells (DCs). By counteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment. The present invention provides strategies to counteract tumor-induced immune tolerance and enhance the antitumor efficacy of chemotherapy by activating and leveraging T cell-mediated adaptive antitumor immunity against resistant or disseminated cancer cells.

IPC Classes  ?

• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C07K 14/495 - Transforming growth factor [TGF]
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 19/00 - Hybrid peptides

Abstract

Nanocarriers are engineered to realize the potential of RNA therapeutics. This work reports the design of pho-to-crosslinked bioreducible nanoparticles (XbNPs) for stable siRNA encapsulation in high serum conditions, shielded surface charge, efficient intracellular trafficking, and triggered cytosolic RNA release. These attributes of XbNPs leads to robust siRNA-mediated knockdown in cancer cells and potent systemic siRNA delivery to tumors in the lungs.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Provided herein are methods of treating a proteinopathy in a subject that include administering an effective amount of a fibrinogen-like protein 1 (FGL1 ), or a functional portion or variant thereof, to the subject having the proteinopathy. The effective amount elevates a level of the FGL1, or the functional portion or variant thereof, in a brain of the subject sufficient to inhibit a binding interaction between a pathogenic protein associated with the proteinopathy and a lymphocyte-activation protein 3 (LAGS) present in the brain of the subject. Related methods, uses, pharmaceutical compositions, and kits are also provided.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

Provided herein are antibody-drug conjugates comprising (a) an antibody or antigen-binding fragment thereof that specifically binds to a T cell receptor β chain constant region (TRBC) polypeptide; and (b) a therapeutic agent conjugated to the antibody or antigen-binding fragment thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

A system for facilitating cardiopulmonary resuscitation (CPR) by a CPR performer on a patient includes first, second, and third sensors configured to be positioned at least partially between a hand of the CPR performer and a chest of the patient. The first sensor is configured to measure a depth of compressions provided by the CPR performer on the patient. The second sensor is configured to measure a rate of the compressions. The third sensor is configured to measure a recoil of the compressions. The system also includes a computing system configured to receive data from the first, second, and third sensors. The computing system is also configured to compare the received data to stored data in a library that corresponds to the received data. The computing system is also configured to generate one or more outputs in response to the comparison.

IPC Classes  ?

• A61H 31/00 - Artificial respiration by a force applied to the chestHeart stimulation, e.g. heart massage
• G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
• G16H 70/20 - ICT specially adapted for the handling or processing of medical references relating to practices or guidelines

Abstract

Analysis of cell-free DNA (cfDNA) fragment ends in patients with cancer provide a direct link between epigenetic changes and cfDNA fragmentation for non-invasive disease detection and treatment of patients.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

An upcycling system for converting plastic waste to value-added aromatic products and process of using same. The system includes a plug-flow reactor with catalytic hydrocracking functionality. Zeolite catalysts can be used to convert the plastic waste, for example marine plastic waste, into aromatic products such as benzene, toluene and/or xylene.

IPC Classes  ?

• C07C 4/06 - Catalytic processes
• B01J 8/00 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes

Abstract

The present disclosure provides agents for detecting cancer based on peptides derived from thymosin beta-10 (Tβ-10) and compositions and methods of use thereof. Particularly, the disclosure provides agents comprising a peptide derived from thymosin beta-10 (Tβ-10) covalently attached to an imaging agent, wherein the peptide comprises less than 20 amino acids and methods of detecting, diagnosing, or imaging cancer.

IPC Classes  ?

• A61K 51/08 - Peptides, e.g. proteins
• A61P 35/00 - Antineoplastic agents

Abstract

Pancreatic adenocarcinoma has the worst overall mortality of any solid tumor, with only 7% of patients surviving after 5 years. To evaluate the clinical implications of genomic alterations in this low cellularity tumor type, we deeply sequenced the genomes of 101 enriched pancreatic adenocarcinomas from patients who underwent potentially curative resections and used non-invasive approaches to examine tumor specific mutations in the circulation of these patients. These analyses revealed somatic mutations in chromatin regulating genes including MLL and ARID1A in 20% of patients that were associated with improved survival. Liquid biopsy analyses of cell free plasma DNA revealed that 43% of patients with localized disease had detectable circulating tumor DNA (ctDNA) in their blood at the time of diagnosis. Detection of ctDNA after resection predicted clinical relapse and poor outcome, and disease recurrence by ctDNA was detected 6.5 months earlier than with standard CT imaging.

IPC Classes  ?

• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/6816 - Hybridisation assays characterised by the detection means
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Provided herein are antisense nucleic acids that targets a 5' upstream open reading frame of an ABCD2 mRNA, wherein the antisense nucleic acid comprises a phosphorodiamidate morpholino backbone. Also provided herein are methods of treating adrenoleukodystrophy (ALD) in a subject in need thereof, the method including administering a therapeutic agent to the subject, wherein the therapeutic agent increases ABCD2 gene expression, thereby treating ALD.

Abstract

Caffeic Acid, L-DOPA, and D-DOPA and prodrugs thereof for treating a disease, condition, or disorder associated with excess glutamate carboxypeptidase II (GCP-II) are disclosed.

IPC Classes  ?

• A61K 31/265 - Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
• A61K 31/24 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/50 - PyridazinesHydrogenated pyridazines
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• C07C 69/732 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
• C07C 69/96 - Esters of carbonic or haloformic acids
• C07C 235/34 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• C07C 235/36 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
• C07C 235/38 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
• C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated

Abstract

The present invention provides biomarkers of oxidative stress in subjects with retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, Fuchs' dystrophy, diabetic macular edema (DME), geographic atrophy, Stargardt's disease, or retinal vein occlusion (RVO), and their use in identifying subjects in need of treatment and methods for staging the severity of the disease.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes

Abstract

Provided are glutamine antagonists and prodrugs of glutamine analogs having formula (I): Provided are glutamine antagonists and prodrugs of glutamine analogs having formula (I): Provided are glutamine antagonists and prodrugs of glutamine analogs having formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R2′, and X are as defined as set forth in the specification, for use in preventing and/or treating acute kidney injury.

IPC Classes  ?

• A61K 31/655 - Azo (—N=N—), diazo (=N2), azoxy (N—O—N or N(=O)—N), azido (—N3) or diazoamino (—N=N—N) compounds
• A61K 31/664 - Amides of phosphorus acids
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

A method for detecting a molecule in a sample includes applying a first filter to an image at a first wavelength. The method also includes applying a second filter to the image at a second wavelength. The method also includes applying a third filter to the image at a third wavelength. The first, second, and third wavelengths are within a predetermined wavelength range, and wherein first, second, and third wavelengths are different from one another. The method also includes detecting a spectral signature for the molecule in the sample in the image after the first, second, and third filters are applied to the image. The method also includes determining whether the molecule is present in the sample based at least partially upon the detected spectral signature.

IPC Classes  ?

• G01N 33/483 - Physical analysis of biological material
• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
• G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Examples may provide a method of segmenting test image data sets obtained from a test subject. The method includes using a first trained machine learning model to segment non-suspicious foci in the test image data set to produce segmented non- suspicious foci data. The test image data set comprises positron emission tomography (PET) images and/or computed tomography (CT) images. The method also includes applying a mask to the non-suspicious foci in the test image data set using the segmented non-suspicious foci data to produce masked and unmasked portions of the test image data set. In addition, the method also includes using a second trained machine learning model and the unmasked portions of the test image data set to segment suspicious foci in the test image data to produce segmented suspicious foci data. Related methods, systems, and computer readable media are also provided.

Abstract

Provided herein are chimeric polypeptides comprising (a) an extracellular domain comprising a cytokine-binding domain and a hinge domain; (b) an extracellular hinge domain; (c) a transmembrane domain; and (d) an intracellular signaling domain.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/54 - Interleukins [IL]
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present disclosure relates to methods of diagnosing lupus nephritis or proliferative lupus nephritis in a subject, methods of predicting a subject's risk of developing lupus nephritis and methods of determine whether a subject suffering from lupus nephritis is responding to treatment. The methods herein involve detecting the presence of or level of at least one biomarker which is IL-16, Galectin-1, CD163, CD206, FOLR2, proteinase 3, or a combination thereof.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A method for adjusting laser control parameters of a laser additive manufacturing system for construction of a part is provided. The method may include performing a laser scan of a building surface, and detecting spectral and intensity response information indicative of at least a temperature at the building surface. The method may also include correlating the spectral and intensity response information with spatial positioning of the laser during the laser scan to generate spatially-correlated spectral and intensity response information. Additionally, the method may include generating a spatial adjustment mask based on the spatially-correlated spectral and intensity response information and a target spatial intensity profile, applying the spatial adjustment mask to spatially-defined laser control parameters, and controlling the laser to perform an additive manufacturing build operation performed in accordance with the target spatial intensity profile due to application of the spatial adjustment mask to construct the part.

IPC Classes  ?

• B22F 10/366 - Scanning parameters, e.g. hatch distance or scanning strategy
• B22F 10/28 - Powder bed fusion, e.g. selective laser melting [SLM] or electron beam melting [EBM]
• B22F 12/41 - Radiation means characterised by the type, e.g. laser or electron beam
• B33Y 30/00 - Apparatus for additive manufacturingDetails thereof or accessories therefor
• B33Y 50/02 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes

Abstract

The present invention relates to compositions and methods for treating vascular Ehlers Danlos Syndrome and associated connective tissue disorders.

IPC Classes  ?

• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/537 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 31/69 - Boron compounds
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers

Abstract

A base station classifier on a portable device includes code for obtaining base station resource allocations, converting the allocations into vectors to provide input to a neural network, and providing access to a trained neural network that evaluates the vectors to identify that a base station is a trusted vendor base station. A method of operations listens to resource allocations of a connected device, converts each allocation into a vector suitable for neural network analysis, evaluates the vector with a trained neural network with to determine if the vector is from a trusted base station, and connects only to base stations indicated by the trained neural network to be a trusted base station.

IPC Classes  ?

• H04L 41/16 - Arrangements for maintenance, administration or management of data switching networks, e.g. of packet switching networks using machine learning or artificial intelligence
• H04W 12/12 - Detection or prevention of fraud
• H04W 72/04 - Wireless resource allocation
• G06F 21/00 - Security arrangements for protecting computers, components thereof, programs or data against unauthorised activity

Abstract

Systems, methods, and computer programs for disambiguating time-series data generating by a monitoring device. In one aspect, the method can include obtaining entity independent time-series data broadcast by a monitoring device, determining, based on the obtained entity independent time-series data, one or more attributes of the entity independent time-series data, generating a query that includes the one or more attributes of the entity independent time-series data, executing the generated query against an entity database to obtain query results that identify an entity, and generating data that associates the obtained entity independent time-series data with the identified entity.

IPC Classes  ?

• G06F 16/2458 - Special types of queries, e.g. statistical queries, fuzzy queries or distributed queries

Abstract

Provided herein are compositions comprising a RIPK2 inhibitor and methods of using the RIPK2 inhibitor for treating or preventing neurodegenerative diseases or disorders. Also provided herein are methods of screening or identifying therapeutic agents useful for treating or preventing neurodegenerative diseases or disorders.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/504 - PyridazinesHydrogenated pyridazines forming part of bridged ring systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/529 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Prodrugs of itaconic acid and 1- and 4-methyl itaconic acid and their use for treating a disease, disorder, or condition associated with inflammation are disclosed.

IPC Classes  ?

• C07C 69/593 - Dicarboxylic acid esters having only one carbon-to-carbon double bond
• C07C 69/90 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with esterified hydroxyl and carboxyl groups
• C07C 229/36 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
• C07C 237/12 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
• C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups

Abstract

Provided herein methods of treating diseases or disorders, particularly primary brain cancers, brain metastases, and other cancers, as well as inflammatory disorders, by directly insonating tissues with low-frequency ultrasound.

IPC Classes  ?

• A61N 7/02 - Localised ultrasound hyperthermia
• A61N 7/00 - Ultrasound therapy

Abstract

The present disclosure relates to methods for performing minimally invasive anatomical space access, e.g., minimally invasive subretinal access (MIS A), in connection with the delivery of therapeutic modalities to an anatomical space of interest, e.g., the subretinal space, and system components adapted to facilitate such delivery.

IPC Classes  ?

• A61F 9/007 - Methods or devices for eye surgery
• A61B 17/34 - TrocarsPuncturing needles
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

Methods for diagnosing a peripheral nervous system (PNS) neuropathy comprising administering to a subject in need of treatment thereof, at least one of a translocator protein (TSPO)-targeting compound or a PSMA-targeting compound and taking an image, are disclosed.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention relates to the field of ribonucleic acid (RNA). More specifically, the present invention provides compositions and methods for highly multiplexed detection of pathogen-associated RNA. In a specific embodiment, a method for forming a target ribonucleic acid (RNA) proxy in a sample comprises the steps of (a) contacting a sample with one or more multi-partite probes that hybridize to a target RNA, wherein the one or more multi-partite probes comprise (i) a target capture probe, (ii) a 3′acceptor probe and (iii) a 5′ phosphorylated donor probe; (b) incubating the sample of step (a) under conditions that allow hybridization of the one or more multi-partite probes to target RNA present in the sample; (c) immobilizing the target capture probes on a solid support; (d) washing away unbound multi-partite probes; and € ligating the acceptor probes and donor probes to form a target RNA proxy.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/25 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving enzymes not classifiable in groups
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6834 - Enzymatic or biochemical coupling of nucleic acids to a solid phase
• C12Q 1/6851 - Quantitative amplification

Abstract

Compositions of dendrimers conjugated with one or more glutamine antagonist(s) that inhibit glutamine metabolism, preferably in activated microglia, and methods of use thereof for treating, alleviating, and/or preventing one or more neurological, oncological, and/or immune disorders associated with pathogenic or dysregulated glutamine-dependent pathways and/or glutamate transmission, have been developed. Dendrimers conjugated with one or more glutamine antagonists effectively inhibit the activity of glutaminase without any systemic toxicity. Dendrimers conjugated with one or more glutamine antagonists accumulate in activated microglia associated with the injured or diseased cells and tissues.

IPC Classes  ?

• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• A61P 35/00 - Antineoplastic agents
• C07C 245/18 - Diazo compounds, i.e. compounds having the free valencies of N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
• C07F 9/22 - Amides of acids of phosphorus

Abstract

Methods for the use of prodrugs of itaconic acid and 1- and 4-methyl itaconic acid for inducing hair growth and treating an inflammatory, or immune activation (adaptive or innate), skin condition or other condition associated with hair loss are disclosed.

IPC Classes  ?

• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61K 31/225 - Polycarboxylic acids
• A61K 31/265 - Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/621 - Salicylic acidDerivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia

Abstract

The invention provides multifunctional antibody-ligand traps and methods of using them to counteract immune tolerance and/or immune dysfunction. The multifunctional antibody-ligand traps and fusion proteins of the invention can counteract immune dysfunction in order to restore and unleash antitumor or pathogen-directed immune responses. Provided here are promising immunotherapeutic agents for treatment and prevention of cancers, infectious diseases, and immuno-inflammatory disorders.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

Broadly-neutralizing antibodies (bNAbs) associated with clearance of human hepatitis C virus (HCV) infection are provided. The bNAbs were generated against a novel mixture of full- length E2 ectodomain proteins to isolate 10,680 E2-reactive B cells from acute infection through multiple spontaneous viral clearance events.

IPC Classes  ?

• C12P 21/00 - Preparation of peptides or proteins
• C12N 15/51 - Hepatitis viruses
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 5/0786 - MonocytesMacrophages
• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 15/13 - Immunoglobulins

Abstract

Methods of recycling target elements include dissolving and/or alloying a metallic component, including one or more target elements, with liquid gallium to provide a gallium melt and exposing the gallium melt with a liquid medium to form an intermediate liquid. The liquid medium is different than the gallium melt. The method also includes adjusting a pH value of the liquid medium to a first target pH and/or adjusting an applied electrical potential value to the intermediate liquid to a first target applied electrical potential, where at least a first portion of an initial total quantity of a first target element is present in a soluble form in the liquid medium. The method further includes isolating the liquid medium from the intermediate liquid to provide a first leachate, and separating the first target element from the first leachate.

IPC Classes  ?

• C22B 59/00 - Obtaining rare earth metals
• C22B 3/06 - Extraction of metal compounds from ores or concentrates by wet processes by leaching in inorganic acid solutions
• C22B 3/16 - Extraction of metal compounds from ores or concentrates by wet processes by leaching in organic solutions
• C22B 3/22 - Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof

Abstract

A catalytic structure has a substrate and a plurality of high-entropy alloy (HEA) nanoparticles. At least a surface layer of the substrate is formed of a metal oxide. The HEA nanoparticles can be formed on the surface layer. Each HEA nanoparticle can comprise a homogeneous mixture of at least four different elements forming a single-phase solid-solution alloy. The catalytic structures can be used to catalyze a chemical reaction, such as an ammonia oxidation reaction, an ammonia synthesis reaction, or an ammonia decomposition reaction.

IPC Classes  ?

• B01J 23/89 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with noble metals
• B01J 21/18 - Carbon
• B01J 35/54 - Bars or plates
• C01B 21/26 - Preparation by catalytic oxidation of ammonia
• C01C 1/04 - Preparation of ammonia by synthesis

Abstract

Provided herein are methods and compositions to augment the efficacy and reduce toxicity of non-engrafting, CD8-depeleted allogeneic donor lymphocyte infusions. The compositions comprise isolated leukocytes obtained from a donor subject that (i) are mismatched to a recipient subject for at least one human leukocyte antigen (HLA) Class II allele mismatch in the donor versus recipient (graft-versus-host) direction relative to the recipient subject or (ii) is mismatched to a recipient subject for at least one human leukocyte antigen (HLA) Class II allele mismatch in the donor versus recipient (graft-versus-host) direction relative to the recipient subject, is matched to the recipient for at least one human leukocyte antigen (HLA) Class II allele, and has CD4+ T cell immunity against an antigen present in a recipient subject.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies